All In Biotech

Drug Trial Radar · NCT07345390

Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris

A Multicenter, Double-blind, Placebo-parallel-controlled Phase Ⅱ Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 in Patients With Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jan 10, 2026

Primary completion

Oct 30, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, efficacy and pharmacokinetics of KR230109 cream compared with placebo in Patients (18-40 Years) with Acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

  • KR230109 cream 0.025%Drug

    KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients

  • KR230109 cream 0.05%Drug

    KR230109 cream 0.05% is indicated for the topical treatment of acne vulgaris in patients

  • PlaceboDrug

    Vehicle cream manufactured to mimic look and feel of KR230109 Cream but without the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change from baseline in the count of non-inflammatory facial lesionsTime frame: week 12
  2. The percentage change from baseline in the count of inflammatory facial lesionsTime frame: week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.